Results 21 to 30 of about 114,558 (301)
Pharmacokinetic Studies of Radiopharmaceuticals
Регуляторные исследования и экспертиза лекарственных средств, 2022 Pharmacokinetic (PK) studies of radiopharmaceuticals (RPs) are distinctive because of small concentrations of active ingredients. Whereas methods applicable to non-RP medicinal products cannot be used for RPs, radionuclide methods can provide an insight ...
A. S. Lunev +2 more
doaj +1 more source
Biomedicines, 2020 Organic cation transporters (OCTs) and novel organic cation transporters (OCTNs) are responsible for drug delivery in the intestine and kidney; in the lung, OCTs mediate inhaled drugs’ transport, although their physiological role in airways remains ...
Amelia Barilli +7 more
doaj +1 more source
EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]
, 2013 EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal +75 more
core +1 more source
Preclinical Transplacental Transfer and Pharmacokinetics of Fipronil in Rats [PDF]
Drug Metabolism and Disposition, 2020 Fipronil, a widely used insecticide and pesticide, with its toxic metabolite fipronil sulfone was detected in fipronil-contaminated eggs as a result of inappropriate use. However, little is known about whether fipronil and fipronil sulfone transfer into fetus through the blood-placenta barrier.
Ya-Ning, Chang, Tung-Hu, Tsai
openaire +2 more sources
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]
, 2018 Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard +16 more
core +2 more sources
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. [PDF]
Curr Drug Metab, 2014 Sucroferric oxyhydroxide (VELPHORO) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the optimal combination of good efficacy, adequate tolerability and low pill burden, sucroferric ...
Cozzolino M +4 more
europepmc +6 more sources
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. [PDF]
, 2016 The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less than 30% of patients with metastatic or recurrent disease survive despite aggressive combinations of chemotherapy, radiation and surgery.
Alturkmani, Hani +11 more
core +3 more sources
Frontiers in Immunology, 2018 Lysinuric protein intolerance (LPI) is a recessively inherited aminoaciduria caused by mutations of SLC7A7, the gene encoding y+LAT1 light chain of system y+L for cationic amino acid transport. The pathogenesis of LPI is still unknown.
Bianca Maria Rotoli +8 more
doaj +1 more source
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study [PDF]
, 2018 BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 ...
Adiwijaya, Bambang S +14 more
core +2 more sources
Molecules, 2023 Novel furoxan/coumarin hybrids were synthesized, and pharmacologic studies showed that the compounds displayed potent antiproliferation activities via downregulating both the phosphatidylinositide 3-kinase (PI3K) pathway and the mitogen-activated protein
Yawen Yuan +11 more
doaj +1 more source